[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-335989-105":59,"doc-detail-335989-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","mael-in-human-cancers-and-implications-in-prognostication-and-predicting-benefit-from-immunotherapy-over-vegfrmtor-inhibitors-in-clear-cell-renal-cell-carcinoma-a-bioinformatic-analysis","MAEL in human cancers and implications in prognostication and predicting benefit from immunotherapy over VEGFR/mTOR inhibitors in clear cell renal cell carcinoma - a bioinformatic analysis","","Maelstrom (MAEL), a cancer/testis-associated gene, is investigated for its role in human malignancies and clinical implications. Single-cell and tissue-bulk transcriptomic analyses show elevated MAEL expression in testis, kidney, and brain, and across several cancer types. In clear cell renal cell carcinoma (ccRCC) only, MAEL expression correlates with recurrence-free survival and overall survival. Higher MAEL aligns with an anti-inflammatory tumor immune microenvironment and VEGFR/mTOR activation, while low MAEL relates to improved progression-free survival under immune checkpoint inhibitor therapies versus VEGFR/mTOR inhibitors in two phase III trials.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/mael-in-human-cancers-and-implications-in-prognostication-and-predicting-benefit-from-immunotherapy-over-vegfrmtor-inhibitors-in-clear-cell-renal-cell-carcinoma-a-bioinformatic-analysis/335989/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/mael-in-human-cancers-and-implications-in-prognostication-and-predicting-benefit-from-immunotherapy-over-vegfrmtor-inhibitors-in-clear-cell-renal-cell-carcinoma-a-bioinformatic-analysis/335989.png","ImageObject",300,407,{"name":92,"@type":93},"Anda","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-08","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the MAEL gene and why is it important in this study?","Question",{"text":112,"@type":113},"MAEL (Maelstrom) is a cancer/testis-associated gene suggested to contribute to tumor initiation and progression, motivating investigation of its biological and clinical relevance.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which cancer type shows the strongest clinical association with MAEL expression?",{"text":117,"@type":113},"Clear cell renal cell carcinoma (ccRCC) is the only cancer type where MAEL expression associates with both recurrence-free survival and overall survival.",{"name":119,"@type":110,"acceptedAnswer":120},"How does MAEL relate to immunotherapy versus VEGFR/mTOR inhibitor treatment outcomes?",{"text":121,"@type":113},"Across two phase III trials, low MAEL expression corresponds to notable progression-free survival benefits from immune checkpoint inhibitor (ICI)-based immunotherapies compared with VEGFR/mTOR inhibitors.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},335989,1790193380,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":4},962075006959,"https://ap-avatar.wpscdn.com/avatar/e0002397efbe92a78e?_k=1776741047341049297","[www.aging-us.com](www.aging-us.com) AGING 2024, Vol. 16, No. 3  \nResearch Paper  \nMAEL in human cancers and implications in prognostication and predicting benefit from immunotherapy over VEGFR/mTOR inhibitors in clear cell renal cell carcinoma: a bioinformatic analysis  \nJin Tao1,*, Jinshan Cui 1,*, Yu Xu2,*, Yafeng Fan 1, *, Guodong Hong 1, Qiaoxia Zhou2, Guoqiang Wang2, Leo Li2, Yusheng Han2, Chunwei Xu 3, Wenxian Wang4, Shangli Cai2, Xuepei Zhang 1  \n1 Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China 2 Burning Rock Biotech, Guangzhou, Guangdong, China  \n3 Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, China 4 Department of Clinical Trial, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China  \n*Equal contribution  \nCorrespondence to: Xuepei Zhang; email: [zhangxuepei@263.net](zhangxuepei@263.net), [https://orcid.org/0000-0003-0919-5871](https://orcid.org/0000-0003-0919-5871)[ ](https://orcid.org/0000-0003-0919-5871)[Keywords:](Keywords: MAEL)[ MAEL](Keywords: MAEL), pan-cancer analysis, clear cell renal cell carcinoma, prognosis, immunotherapy  \nReceived: August 15, 2023 Accepted: December 13, 2023 Published: January 31, 2024  \nCopyright: © 2024 Tao et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.  \nABSTRACT  \nMaelstrom (MAEL), a novel cancer/testis-associated gene, may facilitate the initiation and progression of human malignancies, warranting comprehensive investigations. Single-cell and tissue-bulk transcriptomic data demonstrated higher MAEL expression in testis (spermatogonia/spermatocyte), kidney (proximal tubular cell), and brain (neuron/astrocyte), and corresponding cancers, including testicular germ cell tumor, glioma, papillary renal cell carcinoma, and clear cell renal cell carcinoma (ccRCC) . Of these cancers, only in ccRCC did MAEL expression exhibit associations with both recurrence-free survival and overall survival. High MAEL expression was associated with an anti-inflammatory tumor immune microenvironment and VEGFR/mTOR activation inccRCC tissues and high sensitivities to VEGFR/PI3K-AKT-mTOR inhibitors in ccRCC cell lines. Consistent with these, low rather than high MAEL expression indicated remarkable progression-free survival benefits from immune checkpoint inhibitor (ICI)-based immunotherapies over VEGFR/mTOR inhibitors in two large phase III trials (JAVELIN Renal 101 and CheckMate-025). MAEL is a biologically and clinically significant determinant with potential for prognostication after nephrectomy and patient selection for VEGFR/mTOR inhibitors and immunotherapy-based treatments.  \nINTRODUCTION  \nMaelstrom (MAEL), located in 1q24, is an evolutionarily conserved gene first found in Drosophila oocyte [1] . The full-length MAEL protein contains a high-mobility group (HMG) domain for DNA binding as well as a novel MAEL-specific domain with a single-stranded RNA (ssRNA)-specific endonuclease activity [2–4]. MAEL expression has been discovered by Northern blot in only  \nthe testis of normal human tissues [5], while it has been found to be aberrant in numerous cancer cell lines [5, 6] . Unlike in germ cells, where MAEL is anuage component involved in posttranscriptional piRNAmediated transposon silencing [7], MAEL has been identified as a component of stress granule (SG) in tumor cells [8], relating to the cellular response to abnormal physiological or pathological conditions, such as hypoxia, oxidative stress, and chemotherapeutic drugs [9] .  \nAs a novel cancer/testis-associated gene, MAEL is deemed to participate in stem cell self-renewal that favors tumor proliferation [10] . Emerging evidence has revealed its oncogenic mechanisms in","cbCaiaggNvEyoVLR","https://ap.wps.com/l/cbCaiaggNvEyoVLR","pdf",6582249,33,"English","# Abstract\n# Introduction\n# Materials and Methods\n## Study design and clinical cohorts","[{\"question\":\"What is the MAEL gene and why is it important in this study?\",\"answer\":\"MAEL (Maelstrom) is a cancer/testis-associated gene suggested to contribute to tumor initiation and progression, motivating investigation of its biological and clinical relevance.\"},{\"question\":\"Which cancer type shows the strongest clinical association with MAEL expression?\",\"answer\":\"Clear cell renal cell carcinoma (ccRCC) is the only cancer type where MAEL expression associates with both recurrence-free survival and overall survival.\"},{\"question\":\"How does MAEL relate to immunotherapy versus VEGFR/mTOR inhibitor treatment outcomes?\",\"answer\":\"Across two phase III trials, low MAEL expression corresponds to notable progression-free survival benefits from immune checkpoint inhibitor (ICI)-based immunotherapies compared with VEGFR/mTOR inhibitors.\"}]","MAEL in human cancers and implications in prognostication and predicting benefit from immunotherapy over VEGFR/mTOR inhibitors in clear cell renal cell carcinoma - a bioinformatic analysis | PDF",1790013068,83]